Compare Altria Group Inc (MO) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Nuvalent Inc — how do they compare? Altria Group Inc trades at $73.48 (market cap $124.67B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Altria Group Inc is far larger — about 12.7× Nuvalent Inc's market cap, and Altria Group Inc pays a 5.68% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| MO | NUVL | |
|---|---|---|
Market Cap | $124.67B | $9.81B |
Sector | Consumer Staples | Technology |
52-Week High | $74.66 | $123.96 |
52-Week Low | $54.72 | $72.16 |
Enterprise Value | $145.75B | $8.52B |
Dividend Yield | 5.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $72.99, down 1.64% on the day, with a P/E of 15.59 and strong net income margin of 39.52%. Recent earnings show mixed results, beating estimates in Q1 2026 but missing in Q4 2025. Technical indicators suggest a bullish trend with support at $73 and resistance at $75. The company maintains robust cash flow from operations at $9.29B and declared a $1.06 dividend payable in July 2026.
MO offers a high dividend yield and stable cash flows, appealing for income investors, but faces risks from declining smoking trends and regulatory pressures. Analyst consensus is bullish with a $71 price target, though revenue stagnation and debt levels warrant caution. The stock's defensive qualities provide stability amid market volatility.
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
